These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 9030225

  • 21. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F, Park M, Goltzman D, Rabbani SA.
    Cancer Res; 1997 Oct 15; 57(20):4517-22. PubMed ID: 9377563
    [Abstract] [Full Text] [Related]

  • 22. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y, Vogt A, Sebti SM, Hamilton AD.
    J Med Chem; 1996 Jan 05; 39(1):217-23. PubMed ID: 8568811
    [Abstract] [Full Text] [Related]

  • 23. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
    Agarwal R, Mohan RR, Ahmad N, Mukhtar H.
    Mol Carcinog; 1996 Sep 05; 17(1):13-22. PubMed ID: 8876671
    [Abstract] [Full Text] [Related]

  • 24. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM.
    Oncogene; 2000 Nov 16; 19(48):5525-33. PubMed ID: 11114730
    [Abstract] [Full Text] [Related]

  • 26. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
    Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ.
    Cancer Res; 2001 Mar 01; 61(5):2289-93. PubMed ID: 11280800
    [Abstract] [Full Text] [Related]

  • 27. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity.
    Njoroge FG, Vibulbhan B, Pinto P, Bishop WR, Bryant MS, Nomeir AA, Lin C, Liu M, Doll RJ, Girijavallabhan V, Ganguly AK.
    J Med Chem; 1998 May 07; 41(10):1561-7. PubMed ID: 9572881
    [Abstract] [Full Text] [Related]

  • 28. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM, Ciccarone TM, MacTough SC, Bock RL, Conner MW, Davide JP, Hamilton K, Koblan KS, Kohl NE, Kral AM, Mosser SD, Omer CA, Pompliano DL, Rands E, Schaber MD, Shah D, Wilson FR, Gibbs JB, Graham SL, Hartman GD, Oliff AI, Smith RL.
    J Med Chem; 1996 Mar 29; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract] [Full Text] [Related]

  • 29. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
    deSolms SJ, Giuliani EA, Graham SL, Koblan KS, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Scholz TH, Wiscount CM, Gibbs JB, Smith RL.
    J Med Chem; 1998 Jul 02; 41(14):2651-6. PubMed ID: 9651171
    [Abstract] [Full Text] [Related]

  • 30. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ, Camuso A, Clark J, Fager K, Gullo-Brown J, Hunt JT, Inigo I, Kan D, Koplowitz B, Lee F, McGlinchey K, Qian L, Ricca C, Rovnyak G, Traeger S, Tokarski J, Williams DK, Wu LI, Zhao Y, Manne V, Bhide RS.
    Bioorg Med Chem Lett; 2005 Apr 01; 15(7):1895-9. PubMed ID: 15780629
    [Abstract] [Full Text] [Related]

  • 31. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.
    Clin Cancer Res; 2005 Apr 15; 11(8):3045-54. PubMed ID: 15837760
    [Abstract] [Full Text] [Related]

  • 32. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 33. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL.
    Clin Cancer Res; 1999 Jan 05; 5(1):35-42. PubMed ID: 9918200
    [Abstract] [Full Text] [Related]

  • 34. Basic fibroblast growth factor mediated growth inhibition in breast cancer cells is independent of ras signaling pathway.
    Fenig E, Szyper-Kravitz M, Yerushalmi R, Lahav M, Beery E, Wasserman L, Gutman H, Nordenberg J.
    Oncol Rep; 2002 Jan 05; 9(4):875-7. PubMed ID: 12066225
    [Abstract] [Full Text] [Related]

  • 35. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.
    Leonard DM, Shuler KR, Poulter CJ, Eaton SR, Sawyer TK, Hodges JC, Su TZ, Scholten JD, Gowan RC, Sebolt-Leopold JS, Doherty AM.
    J Med Chem; 1997 Jan 17; 40(2):192-200. PubMed ID: 9003517
    [Abstract] [Full Text] [Related]

  • 36. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
    Nakamura K, Yamaguchi A, Namiki M, Ishihara H, Nagasu T, Kowalczyk JJ, Garcia AM, Lewis MD, Yoshimatsu K.
    Oncol Res; 2001 Jan 17; 12(11-12):477-84. PubMed ID: 11939411
    [Abstract] [Full Text] [Related]

  • 37. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS.
    Leukemia; 2003 Feb 17; 17(2):451-7. PubMed ID: 12592346
    [Abstract] [Full Text] [Related]

  • 38. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG.
    Cancer Res; 1996 Apr 15; 56(8):1727-30. PubMed ID: 8620483
    [Abstract] [Full Text] [Related]

  • 39. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor.
    Charvat S, Duchesne M, Parvaz P, Chignol MC, Schmitt D, Serres M.
    Anticancer Res; 1999 Apr 15; 19(1A):557-61. PubMed ID: 10226598
    [Abstract] [Full Text] [Related]

  • 40. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ, Guitton JD, Baudoin B, Lelièvre Y, Duchesne M, Parker F, Fromage N, Commerçon A.
    J Med Chem; 1997 Jun 06; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.